RedHill Biopharma Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $4.3M
- Price
- $0.71
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.15%
- Volume
- 59.4K
Quote data as of 7:08 AM ET
About
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Quick stats
Shares outstanding6.1M
Computed float2.3M
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001553846
Websitehttps://www.redhillbio.com
AI Summary
AI-generated1mo agostandardbullishregulatoryRedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
RedHill Biopharma (RDHL) announced that the FDA granted rare pediatric disease designation to its investigational drug opaganib for the treatment of neuroblastoma.
This designation, added to existing orphan drug status, provides potential benefits including a Priority Review Voucher, accelerated review times, and seven years of marketing exclusivity if approved.
Cumberland Pharmaceuticals (CPIX) is the U.S. co-commercialization partner for RedHill's approved drug Talicia, linking CPIX to RedHill's broader pipeline developments, though opaganib is not part of the Talicia agreement.